Navigation Links
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Date:5/9/2008

r corporate headquarters and research laboratories to San

Diego's biotechnology corridor.

2008 1st Quarter Financial Results

As of March 31, 2008, the Company had $56.2 million in cash, cash equivalents and short-term investments, compared to $66.2 million as of December 31, 2007.

The net loss for the first quarter ended March 31, 2008 was $12.4 million, or $0.93 per share, compared to a net loss for the same period in 2007 of $3.4 million, or $0.37 per share. The net loss included non-cash stock-based compensation expense of $1.0 million, or $0.08 per share, and $0.2 million, or $0.02 per share, for the three months ended March 31, 2008 and March 31, 2007, respectively. The increase in net loss between these two periods was primarily due to increased expenses resulting from our continued progress with our preclinical and clinical drug candidates.

Revenue for the first quarter was $0.3 million, compared to $0.9 million for the same period in 2007. The decrease is the result of fewer research activities performed by us under our master services agreement with Valeant Pharmaceuticals ("Valeant"). Due to changing priorities at Valeant, we do not anticipate any additional research activities to be conducted under the master services agreement.

2008 Financial Guidance

The Company confirmed its financial guidance for the full year ending December 31, 2008. Excluding any funds that Ardea may receive from future business development activities, the Company anticipates 2008 net cash usage to be between $45 million and $50 million.

About Ardea Biosciences

Ardea Biosciences, Inc. of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candi
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 16, 2011 /PRNewswire-Asia-FirstCall/ -- China ... (Nasdaq: CMED ), ... diagnostic ("IVD") company, today announced ... at the following investor conferences ...
... artery disease (CAD), also known as coronary heart disease, ... affecting about 17 million Americans(1). Most of these people ... angina pectoris. For over 100 years, physicians have treated ... nitroglycerin(2). Considered the gold standard in treating acute angina, ...
Cached Medicine Technology:China Medical Technologies to Meet Investors 2Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray 2Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray 3Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray 4
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... important organs in the human body. Its job is ... this is its synthesis function and that toxic ... its detoxification function. Lack of exercise and too much ... The resulting diseased cells can lead to inflammations, cancerous ... to the German Liver Foundation, over five million people ...
(Date:7/9/2014)... July 9, 2014 A study published in the ... Koninck and Robert Bonin, two researchers at Universit Laval, ... using a new method that involves rekindling pain so ... lead to novel means to alleviate chronic pain. , ... Laval and Institut universitaire en sant mentale de Qubec ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... Alliance Leverages the Adify Platform to Aggregate Leading ... Baby Boomers Caring for Aging Parents, SAN ... a comprehensive online resource for people caring,for aging ... ), the first vertical ad,network to reach baby ...
... 2008A team of Universit Laval researchers has shown that the ... brains of mice fed a diet rich in animal fat ... diets typical of most industrialized countries promote the development of ... of Aging . , To demonstrate this, the team led ...
... will add significant growth to the ... company,s first aid ... Bulletin Board: DSCI) announced today that it has secured two,additional ... the highly popular and growing segment of printed,bandages allows for ...
... Month, SANTA MONICA, Calif., Oct. 28 /PRNewswire/ - ... coined to express the benefits of keeping physically fit,but ... Numerous studies,have shown that regular brain training sessions -- ... help stave off dementia and even the,symptoms of Alzheimer,s ...
... study between leading researchers in academia and industry from US, Australian ... 293 cell growth and productivity using protein derived from colostrum. ... ... A recent breakthrough was published in the scientific journal In Vitro ...
... LeonardoMD is pleased to announce that Medical Reimbursement ... Web-based practice management software to automate their high-volume ... billing for several dozen providers using LeonardoMD over ... outcome. LeonardoMD takes pride in working with ...
Cached Medicine News:Health News:Caring.com Launches First Ad Network to Reach Family Caregivers 2Health News:A high-fat diet could promote the development of Alzheimer's 2Health News:Derma Sciences Announces 3-Year Licensing Deals for Highly Profitable Character Strip Bandages 2Health News:10 Surprising Facts About Using Brain Training to Fight Dementia 2Health News:10 Surprising Facts About Using Brain Training to Fight Dementia 3Health News:Global Scientific Research Collaboration Leads to Breakthrough in Culturing HEK 293 Cells in Animal-free Media 2Health News:Medical Reimbursement Consultants, Inc. Selects LeonardoMD for Web-based Medical Billing 2Health News:Medical Reimbursement Consultants, Inc. Selects LeonardoMD for Web-based Medical Billing 3
For use with cushioned neckband....
... PVC siliconized. Stainless steel spiral reinforced. X-ray ... use. Adjustable Flange: The flange can be ... the thickness of the cervical soft tissue. ... the flange is tightly connected to the ...
... The permanent flexible tube ... of the neck flange helps ... neck, chin, and stoma, enhancing ... ,Bivona® FlexTend™ tracheostomy tubes ...
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Medicine Products: